|
| Press Releases |
|
 |
|
| Tuesday, June 2, 2020 |
|
|
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020. more info >> |
|
| Friday, May 29, 2020 |
|
|
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody |
| AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (Q2W) regimen as a treatment option for patients with hidradenitis suppurativa (HS) after the first 4 weeks of treatment. more info >> |
|
|
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials |
| The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively. more info >> |
|
| Monday, May 18, 2020 |
|
|
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules |
| Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020. more info >> |
|
| Thursday, May 14, 2020 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate and eribulin mesylate will be given at the American Society of Clinical Oncology, from May 29 to 31, 2020. more info >> |
|
| Monday, April 27, 2020 |
|
|
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine |
| This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector. more info >> |
|
| Wednesday, April 1, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China |
| Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. more info >> |
|
| Thursday, March 26, 2020 |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant) |
| Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL). more info >> |
|
| Wednesday, March 25, 2020 |
|
|
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase inhibitor discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development '20 by the PSJ. more info >> |
|
| Monday, March 23, 2020 |
|
|
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health) |
| Eisai Co., Ltd. announced today that it will launch "NouKNOWTM", a new digital tool (non-medical device) for self-assessment of brain performance (brain health). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
SGL Golf Launches in U.S. Market to Meet Demand for Autonomous Course Management Solutions 
Feb 3, 2026 3:00 JST
|
|
|
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Feb 2, 2026 22:00 HKT/SGT
|
|
|
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor
Feb 2, 2026 20:30 HKT/SGT
|
|
|
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Feb 2, 2026 20:00 HKT/SGT
|
|
|
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 2, 2026 16:29 JST
|
|
|
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 2, 2026 14:30 JST
|
|
|
COSMOPlat, Serving 160,000 Firms, Files for Hong Kong IPO on "AI+Industrial Internet" Wave
Feb 2, 2026 13:29 HKT/SGT
|
|
|
Muyuan Foods IPO: Hog Giant's Profit Growth Outpaces Top 10 Global Meat Firms, Eyes Global Expansion
Feb 2, 2026 13:17 HKT/SGT
|
|
|
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 2, 2026 10:00 JST
|
|
|
Web-based tool makes it easier to design advanced materials
Feb 2, 2026 08:00 HKT/SGT
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 17:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00 HKT/SGT
|
|
|
REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
Jan 31, 2026 02:40 HKT/SGT
|
|
|
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 21:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
